Vical Incorporated TransVax(tm) CMV Vaccine Achieves Promising Interim Clinical Results in Phase 2 Trial

SAN DIEGO, July 8, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that its TransVax(tm) therapeutic DNA cytomegalovirus (CMV) vaccine provided promising results compared with placebo across a broad range of clinical efficacy endpoints at the four-month interim analysis in an ongoing Phase 2 trial. The trial is evaluating the potential for TransVax(tm) to prevent CMV reactivation in immunosuppressed CMV-seropositive hematopoietic stem cell transplant (HCT) recipients, which could reduce antiviral usage and CMV-associated disease. The interim efficacy data for evaluable subjects, unblinded by treatment groups, also reinforced encouraging immunogenicity data from an initial group of HCT recipients in the trial reported previously in the fourth quarter of 2008. The company expects the trial to be completed in the fourth quarter of 2009, and to have final data available in the first half of 2010.

Back to news